Show simple item record

dc.contributor.authorBehrendt, Patrick
dc.contributor.authorSteinmann, Eike
dc.contributor.authorManns, Michael P
dc.contributor.authorWedemeyer, Heiner
dc.date.accessioned2015-03-12T15:28:20Zen
dc.date.available2015-03-12T15:28:20Zen
dc.date.issued2014-12en
dc.identifier.citationThe impact of hepatitis E in the liver transplant setting. 2014, 61 (6):1418-29 J. Hepatol.en
dc.identifier.issn1600-0641en
dc.identifier.pmid25195557en
dc.identifier.doi10.1016/j.jhep.2014.08.047en
dc.identifier.urihttp://hdl.handle.net/10033/346563en
dc.description.abstractHepatitis E virus (HEV) infection has been identified as a cause of graft hepatitis in liver transplant recipients. The true frequency and clinical importance of HEV infections after liver transplantations is a matter of debate. It is proposed that consumption of HEV-contaminated undercooked meat is a main source for HEV infections in developed countries--which might also account for some hepatitis E cases after organ transplantation. However, HEV is also transmitted by transfusion of blood products, likely representing a previously underestimated risk particularly for patients in the transplant setting. HEV infection can take chronic courses in immunocompromised individuals, associated in some cases with rapid progression to cirrhosis within 1-2 years of infection. Diagnosis in transplanted patients is based on HEV RNA testing as antibody assays are not sensitive enough. Selection of immunosuppressive drugs is important as different compounds may influence viral replication and the course of liver disease. Ribavirin has antiviral activity against HEV and should be administered for at least three months in chronically infected individuals; however, treatment failure may occur. HEV infections have also been linked to a variety of extrahepatic manifestations both during and after resolution of infection. In this review we summarize the emerging data on hepatitis E with a particular focus on the importance of HEV infections for liver transplant recipients.
dc.language.isoenen
dc.titleThe impact of hepatitis E in the liver transplant setting.en
dc.typeArticleen
dc.identifier.journalJournal of hepatologyen
refterms.dateFOA2018-06-12T22:06:03Z
html.description.abstractHepatitis E virus (HEV) infection has been identified as a cause of graft hepatitis in liver transplant recipients. The true frequency and clinical importance of HEV infections after liver transplantations is a matter of debate. It is proposed that consumption of HEV-contaminated undercooked meat is a main source for HEV infections in developed countries--which might also account for some hepatitis E cases after organ transplantation. However, HEV is also transmitted by transfusion of blood products, likely representing a previously underestimated risk particularly for patients in the transplant setting. HEV infection can take chronic courses in immunocompromised individuals, associated in some cases with rapid progression to cirrhosis within 1-2 years of infection. Diagnosis in transplanted patients is based on HEV RNA testing as antibody assays are not sensitive enough. Selection of immunosuppressive drugs is important as different compounds may influence viral replication and the course of liver disease. Ribavirin has antiviral activity against HEV and should be administered for at least three months in chronically infected individuals; however, treatment failure may occur. HEV infections have also been linked to a variety of extrahepatic manifestations both during and after resolution of infection. In this review we summarize the emerging data on hepatitis E with a particular focus on the importance of HEV infections for liver transplant recipients.


Files in this item

Thumbnail
Name:
Publisher version
Thumbnail
Name:
Behrendt et al_final.pdf
Size:
1.264Mb
Format:
PDF
Description:
Open Access article

This item appears in the following Collection(s)

Show simple item record